Buprenorphine/naloxone vs methadone for the treatment of opioid use disorder

B. NOSYK ; J. E. MIN ; F. HOMAYRA ; M. KURZ ; B. C. GUERRA-ALEJOS ; R. YAN ; M. PISKE ; S. R. SEAMAN ; P. BACH ; S. GREENLAND ; M. E. KARIM ; U. SIEBERT ; J. BRUNEAU ; P. GUSTAFSON ; K. KAMPMAN ; P. T. KORTHUIS ; T. LOUGHIN ; L. C. MCCANDLESS ; R. W. PLATT ; K. T. SCHNEPEL ; M. E. SOCIAS | 2024
Dans Journal of the American Medical Association (Vol.332, n°21, December 3, 2024) Article : Périodique

Key points: Question: Is buprenorphine/naloxone associated with lower risk of treatment discontinuation and mortality compared with methadone? Findings: In this population-based retrospective cohort study that included 30?891 individuals initi[...]

Plus d'info

Ajouter à la sélection

Lien externe

Nouveauté

Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada

M. KURZ ; B. C. GUERRA-ALEJOS ; J. E. MIN ; S. R. SEAMAN ; M. PISKE ; P. BACH ; J. BRUNEAU ; S. GREENLAND ; P. GUSTAFSON ; K. KAMPMAN ; M. E. KARIM ; P. T. KORTHUIS ; R. W. PLATT ; U. SIEBERT ; M. E. SOCIAS ; E. WOOD ; B. NOSYK | 2025
Dans Addiction (Vol.120, n°12, December 2025) Article : Périodique

BACKGROUND AND AIM: Urine drug testing is often utilized alongside opioid agonist treatment to assess client progress by validating self-reported substance use, monitoring for diversion and supporting clinical decisions for take-home dosing. How[...]

Plus d'info

Ajouter à la sélection

Lien externe